Clinical Trial Update: Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial is evaluating Envafolimab in combination with Disitamab Vedotin and Carboplatin for resectable HER2-mutant non-small cell lung cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Disitamab Vedotin (disitamab vedotin)
• Envafolimab (envafolimab)

Snippet

Sponsor: Guangdong Provincial People's Hospital | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: RECRUITING